Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 276 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergic Rhinosinusitis Clear all
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

NCT00854360
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hayfever
Interventions
Beclomethasone dipropionate HFA Nasal Aerosol, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
26
States / cities
Mission Viejo, California • San Diego, California • Colorado Springs, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)

NCT00197262
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
GW685698X Aqueous Nasal Spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
18
States / cities
Chicago, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects

NCT01171664
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, STAHIST
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
South Bend, Indiana • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional Results available

Effects of Whole Sprouts on Airway Allergic Inflammation

NCT01522703
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Allergy
Interventions
Broccoli Sprouts, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00651118
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)

NCT00346775
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate, Flunisolide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
7
States / cities
Fresno, California • Napa, California • Roseville, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00660517
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
MP29-02, azelastine Hcl, fluticasone propionate, placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00682643
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
fluticasone furoate nasal spray, vehicle placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
56
States / cities
Oxford, Alabama • Little Rock, Arkansas • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Mite Asthma Pediatric Immunotherapy Trial

NCT03654976
View directory record Official record
Conditions
Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
Interventions
HDM SLIT-tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
5 Years to 17 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Miami, Florida • Columbus, Georgia • Ypsilanti, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

NCT01697956
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
BDP, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Long Beach, California • Stockbridge, Georgia • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

NCT00845195
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

NCT00979615
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
Olopatadine HCL (Patanase) Nasal Spray, 0.6%, Azelastine HCl (Astelin) Nasal Spray, 137 mcg
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Molekule for Allergic Rhinitis/Asthma

NCT03627689
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Active air purifier in respiratory allergies/asthma, Sham air purifier
Other
Lead sponsor
Molekule
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

NCT00296491
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP), placebo nasal, ADVAIR DISKUS, placebo capsule, placebo DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
104
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

NCT03887026
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

NCT00628108
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine 1.25 mg, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Months to 11 Months
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Broccoli Sprout Extract on Allergy Rhinitis

NCT02885025
View directory record Official record
Conditions
Rhinitis,Allergic
Interventions
Broccoli Sprout Extract, fluticasone nasal, broccoli sprout extract placebo, normal saline nasal spray
Dietary Supplement · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

NCT05540717
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Interventions
PQ Grass, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
33
States / cities
Centennial, Colorado • Denver, Colorado • Lexington, Kentucky + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

NCT02696850
View directory record Official record
Conditions
Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
Interventions
Budesonide, Saline alone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Evaluation of Ten Allergy Skin Prick Test Devices

NCT03509766
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Food Allergy, Skin Testing
Interventions
Histamine skin testing
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarkers of Cockroach Sublingual Immunotherapy 2

NCT01380327
View directory record Official record
Conditions
Asthma, Perennial Allergic Rhinitis
Interventions
Cockroach Sublingual Immunotherapy (SLIT) - Low Dose, Placebo, Cockroach Sublingual Immunotherapy (SLIT) - High Dose
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 17 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

NCT00806754
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide nasal spray + placebo Azelastine, Ciclesonide nasal spray + Azelastine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Encinitas, California • Los Angeles, California • Mission Viejo, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 21, 2026, 6:59 AM EDT